TCGA-MP-A4T7-01A-11R-A24X-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.330
- TNFA_SIGNALING_VIA_NFKB+0.320
- XENOBIOTIC_METABOLISM+0.320
- ESTROGEN_RESPONSE_LATE+0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- ESTROGEN_RESPONSE_EARLY+0.240
- PANCREAS_BETA_CELLS+0.240
- ADIPOGENESIS+0.210
- BILE_ACID_METABOLISM+0.210
- OXIDATIVE_PHOSPHORYLATION+0.210
Top 10 suppressed
- E2F_TARGETS-0.470
- MYC_TARGETS_V1-0.460
- G2M_CHECKPOINT-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- HEDGEHOG_SIGNALING-0.390
- PROTEIN_SECRETION-0.370
- DNA_REPAIR-0.350
- MYC_TARGETS_V2-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.330
- MTORC1_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD025_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.801 |
| 2 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.778 |
| 3 | SJEPD011_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.757 |
| 4 | TCGA-91-8496-01A-11R-2403-07 | — | cohortA1 | 0.754 |
| 5 | TCGA-CF-A47S-01A-11R-A23W-07 | — | — | 0.749 |
| 6 | MBCProject_0217_T2_RNA | — | C | 0.748 |
| 7 | C3L-00368 | — | cohortA1 | 0.747 |
| 8 | SRR4296108 | — | cohortA1 | 0.742 |
| 9 | TCGA-E9-A3Q9-01A-11R-A21T-07 | — | B | 0.742 |
| 10 | TCGA-OL-A5RU-01A-11R-A28M-07 | — | A | 0.738 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |